Cellsource Co Ltd receives Investment Bank Analyst Rating Update
- Investing.com
Pro
CellSource Co., Ltd. engages in the regenerative medicine-related businesses in Japan. The company provides processing services to extract adipose-derived stem cells from patients’ adipose tissues, and to prepare platelet-rich plasma from patients’ blood; and offers support services for medical facilities providing regenerative medicine therapy. It is also involved in the sale of human stem cell-derived cosmetic ingredients; and Signalift series of anti-aging products, including a serum. The company was incorporated in 2015 and is headquartered in Shibuya, Japan.
Metrics to compare | 4880 | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship Relationship4880PeersSector | |
|---|---|---|---|---|
P/E Ratio | 818.8x | −4.5x | −0.5x | |
PEG Ratio | - | −0.27 | 0.00 | |
Price/Book | 1.4x | 1.6x | 2.6x | |
Price / LTM Sales | 2.2x | 2.0x | 3.3x | |
Upside (Analyst Target) | 113.1% | 18.9% | 45.0% | |
Fair Value Upside | Unlock | 6.0% | 5.1% | Unlock |